Preventive mastectomy, attention to the Angelina Jolie effect!

In May 2013, a publication in the New York Times caused a great stir: actress Angelina Jolie announced a double mastectomy, which requires the selection of a mutation specific to the BRCA1 or BRCA2 genes for this operation. The main risk is breast or ovarian cancer. Angelina Jolie’s mother died of cancer at the age of 56, and the 37-year-old actress was waiting for this radical and militant decision in the media.

In foul, at the Bergonier Institute, the number of hits on the film multiplies. Des femmes reconnus comme “risk”, de toute la région et même au-delà, souhaitaient l’Operation d’Angelina. In France, a woman over 1000 years old will be born with these genes.

However, BRCA genes are not the cause of unexpected cancer in oneself, other existing facts noted by previous families of cancer in oneself and ovaries. If among the university states plus 40% of women are considered risky decedents of their fair activities, then in France they are 20%. There is a good chance that an aspect of American intervention in health matters is the same as the health care system itself, in particular in the refusal to reimburse per capita costs: il cûte moins cher de se faire opérer que de soigner un cancer.

“Prophylactic mastectomy for predisposition is a preventive measure aimed at women without a test-confirmed hereditary predisposition syndrome. This operation is a proposal, an alternative to accessible observation,” Dr. Michel Longy, geneticist at the Bergonier Institute, confirmed in our columns in 2013. The rest of the world confirms: last year Bergoni identified one hundred women of different genders. Prophylactic mastectomy, if scientifically effective, is still a high-profile and traumatic protocol.